Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107523 · ClinicalTrials.gov registry record · Phase 1
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00107523 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00107523, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may help idarubicin and cytarabine work better by making cancer cells more sensitive to the drugs. Giving pravastatin together with idarubicin and cytarabine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of pravastatin when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia.
Interventions
- DRUG cytarabine
- DRUG idarubicin
- DRUG pravastatin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107523
The ClinicalTrials.gov registry entry for NCT00107523 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cytarabine is the first listed.
NCT00107523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107523 about?
NCT00107523 is a clinical study titled "Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may help idarubicin and cytarabine work better by making cancer cells more sensitive to the ...
What is the current status of trial NCT00107523?
This trial is currently completed. It is a Phase 1 study. The study started on 2005-01. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00107523?
The interventions under investigation include: cytarabine (DRUG), idarubicin (DRUG), pravastatin (DRUG).
Who is sponsoring clinical trial NCT00107523?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.